$DMAC
DiaMedica Therapeutics Inc.

2020 Q3 Form 10-Q Financial Statement

#000143774920022537 Filed on November 04, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q3 2019 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.140M $1.040M $870.0K
YoY Change 9.62% 33.33% -18.69%
% of Gross Profit
Research & Development $2.158M $1.617M $1.874M
YoY Change 33.46% 33.64% 75.14%
% of Gross Profit
Depreciation & Amortization $10.00K $10.00K $0.00
YoY Change 0.0% -100.0%
% of Gross Profit
Operating Expenses $2.158M $1.617M $1.874M
YoY Change 33.46% 33.64% 75.14%
Operating Profit -$3.319M -$2.661M -$2.741M
YoY Change 24.73% 78.95% 48.16%
Interest Expense $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $128.0K $225.0K -$280.0K
YoY Change -43.11% 43.31% -313.74%
Pretax Income -$3.191M -$2.436M -$2.461M
YoY Change 30.99% 83.16% 43.16%
Income Tax $2.000K $12.00K $8.000K
% Of Pretax Income
Net Earnings -$3.193M -$2.448M -$2.469M
YoY Change 30.43% 76.5% 42.31%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$191.1K -$204.0K -$206.2K
COMMON SHARES
Basic Shares Outstanding 18.74M 12.01M 11.96M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $30.60M $9.741M $10.97M
YoY Change 214.11% 149.77% 93.89%
Cash & Equivalents $9.797M $4.741M $2.974M
Short-Term Investments $20.80M $5.000M $8.000M
Other Short-Term Assets $150.0K $400.0K $200.0K
YoY Change -62.5% 150.0% 81.82%
Inventory
Prepaid Expenses
Receivables $335.0K $664.0K $1.112M
Other Receivables $0.00 $0.00
Total Short-Term Assets $31.11M $10.81M $12.28M
YoY Change 187.86% 112.72% 102.57%
LONG-TERM ASSETS
Property, Plant & Equipment $50.00K $68.00K $73.00K
YoY Change -26.47% -24.44% 4.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $270.0K
YoY Change -100.0% 3.85%
Total Long-Term Assets $164.0K $233.0K $521.0K
YoY Change -29.61% -31.47% 57.88%
TOTAL ASSETS
Total Short-Term Assets $31.11M $10.81M $12.28M
Total Long-Term Assets $164.0K $233.0K $521.0K
Total Assets $31.27M $11.04M $12.80M
YoY Change 183.27% 103.67% 100.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $720.0K $312.0K $262.0K
YoY Change 130.77% -22.0% -55.59%
Accrued Expenses $658.0K $837.0K $630.0K
YoY Change -21.39% 7.31% 70.27%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $10.00K $10.00K $10.00K
YoY Change 0.0%
Total Short-Term Liabilities $1.443M $1.205M $947.0K
YoY Change 19.75% -17.47% -23.63%
LONG-TERM LIABILITIES
Long-Term Debt $10.00K $10.00K $20.00K
YoY Change 0.0%
Other Long-Term Liabilities $60.00K $120.0K $130.0K
YoY Change -50.0% -95.42% -96.47%
Total Long-Term Liabilities $69.00K $134.0K $148.0K
YoY Change -48.51% -94.89% -95.98%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.443M $1.205M $947.0K
Total Long-Term Liabilities $69.00K $134.0K $148.0K
Total Liabilities $1.512M $1.339M $1.095M
YoY Change 12.92% -67.18% -77.74%
SHAREHOLDERS EQUITY
Retained Earnings -$64.71M -$54.14M -$51.69M
YoY Change 19.53%
Common Stock $0.00 $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $29.76M $9.700M $11.70M
YoY Change
Total Liabilities & Shareholders Equity $31.27M $11.04M $12.80M
YoY Change 183.27% 103.67% 100.27%

Cashflow Statement

Concept 2020 Q3 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income -$3.193M -$2.448M -$2.469M
YoY Change 30.43% 76.5% 42.31%
Depreciation, Depletion And Amortization $10.00K $10.00K $0.00
YoY Change 0.0% -100.0%
Cash From Operating Activities -$2.350M -$1.230M -$2.880M
YoY Change 91.06% -33.15% 182.35%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$14.00M $3.000M $3.010M
YoY Change -566.67%
Cash From Investing Activities -$14.00M $3.000M $3.010M
YoY Change -566.67% -15100.0% -30200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $23.00M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 21.18M 0.000 70.00K
YoY Change -100.0% 40.0%
NET CHANGE
Cash From Operating Activities -2.350M -1.230M -2.880M
Cash From Investing Activities -14.00M 3.000M 3.010M
Cash From Financing Activities 21.18M 0.000 70.00K
Net Change In Cash 4.830M 1.770M 200.0K
YoY Change 172.88% -196.72% -120.41%
FREE CASH FLOW
Cash From Operating Activities -$2.350M -$1.230M -$2.880M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$2.350M -$1.230M -$2.880M
YoY Change 91.06% -32.42% 185.15%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 dmac Accrued Clinical Study Costs Current
AccruedClinicalStudyCostsCurrent
211000
CY2019Q4 dmac Accrued Clinical Study Costs Current
AccruedClinicalStudyCostsCurrent
433000
CY2020Q3 dmac Accrued Research And Professional Fees Current
AccruedResearchAndProfessionalFeesCurrent
94000
CY2019Q4 dmac Accrued Research And Professional Fees Current
AccruedResearchAndProfessionalFeesCurrent
172000
CY2020Q3 dmac Accrued Taxes And Other Liabilities Current
AccruedTaxesAndOtherLiabilitiesCurrent
13000
CY2019Q4 dmac Accrued Taxes And Other Liabilities Current
AccruedTaxesAndOtherLiabilitiesCurrent
52000
CY2020Q3 dmac Income From Governmental Assistance
IncomeFromGovernmentalAssistance
25000
CY2019Q3 dmac Income From Governmental Assistance
IncomeFromGovernmentalAssistance
263000
dmac Income From Governmental Assistance
IncomeFromGovernmentalAssistance
205000
dmac Income From Governmental Assistance
IncomeFromGovernmentalAssistance
663000
dmac Noncash Lease Expense
NoncashLeaseExpense
39000
dmac Noncash Lease Expense
NoncashLeaseExpense
36000
CY2020Q3 dmac Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
21200000
CY2020Q1 dmac Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
7700000
CY2020Q3 dmac Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
289000
CY2019Q4 dmac Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
793000
CY2020Q3 dmac Working Capital
WorkingCapital
29700000
CY2020Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
658000
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1076000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
64232000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
508000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
451000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1337000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
763000
CY2020Q3 us-gaap Assets
Assets
31270000
CY2019Q4 us-gaap Assets
Assets
9053000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
720000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
182000
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
335000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
823000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
658000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1076000
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
59000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
43000
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
10000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2000
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
94457000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
31106000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
8836000
CY2020Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
164000
CY2019Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
217000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9797000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3883000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4741000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5914000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12082000
CY2020Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
9800000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3883000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16823000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9797000
CY2020Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2815067
CY2020Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2019Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2019 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18739074
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12006874
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18739074
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12006874
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3212000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2453000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8084000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8163000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Concentration of credit risk</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains its cash balances primarily with <div style="display: inline; font-style: italic; font: inherit;">two</div> financial institutions. These balances generally exceed federally insured limits. The Company has <div style="display: inline; font-style: italic; font: inherit;">not</div> experienced any losses in such accounts and believes it is <div style="display: inline; font-style: italic; font: inherit;">not</div> exposed to any significant credit risk in cash and cash equivalents. The Company believes that the credit risk related to marketable securities is limited due to the adherence to an investment policy focused on the preservation of principal.</div></div></div>
CY2020Q3 us-gaap Deposits Assets Current
DepositsAssetsCurrent
10000
CY2019Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
88000
us-gaap Depreciation
Depreciation
16000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3191000
CY2019Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
182000
us-gaap Depreciation
Depreciation
16000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.55
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
340000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
419000
CY2020Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
6000
CY2019Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
6000
CY2020Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
8000
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
13000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
4000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
4000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1139000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1044000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3241000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2725000
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2436000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-8072000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-8140000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
29000
CY2020Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
CY2019Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
13000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
538000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-171000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-488000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-116000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-458000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1000
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-78000
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
39000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
91000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-280000
CY2020Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
38000
CY2019Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
17000
us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
24000
us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
68000
CY2020Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.09
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
131000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
68000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
46000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
17000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
11000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31270000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9053000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1443000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1318000
CY2020Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
69000
CY2019Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
118000
CY2020Q3 us-gaap Marketable Securities
MarketableSecurities
20800000
CY2020Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
20826000
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
3995000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
28884000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
71000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16801000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4916000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6169000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7237000
us-gaap Net Income Loss
NetIncomeLoss
-8092000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2425000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-2474000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-3193000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-3252000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-2469000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-2448000
us-gaap Net Income Loss
NetIncomeLoss
-8169000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
128000
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
225000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
359000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
683000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3319000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2661000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8431000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8823000
us-gaap Operating Lease Cost
OperatingLeaseCost
49000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
120000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
59000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
54000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
61000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
105000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
114000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
25048000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
10928000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
153000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
40000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-13000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-19000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3000
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8000
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
103000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-38000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
154000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
20000
CY2020Q3 us-gaap Other Receivables
OtherReceivables
8000
CY2019Q4 us-gaap Other Receivables
OtherReceivables
us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
-12000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
138000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
47000
CY2020Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
23000000
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8500000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
28872000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
8249000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
6000000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
16000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
75000
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
109000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
107000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
64000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2180000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1617000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5190000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6098000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-64709000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56617000
us-gaap Share Based Compensation
ShareBasedCompensation
1337000
us-gaap Share Based Compensation
ShareBasedCompensation
763000
CY2020Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
887751
CY2020Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1395399
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P7Y73D
CY2020Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
5.24
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y292D
CY2020Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
5
CY2020Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
4
CY2020Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
393000
CY2020Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
436000
CY2020Q3 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
508000
CY2020Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4600000
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2125000
CY2019Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
130000
CY2019Q3 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
451000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7682000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
21190000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
75000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
29758000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
7617000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
13323000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
11272000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
17025000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
13906000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
11702000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
9700000
us-gaap Variable Lease Cost
VariableLeaseCost
40000
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16689074
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12006874
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14652749
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11981233

Files In Submission

Name View Source Status
0001437749-20-022537-index-headers.html Edgar Link pending
0001437749-20-022537-index.html Edgar Link pending
0001437749-20-022537.txt Edgar Link pending
0001437749-20-022537-xbrl.zip Edgar Link pending
dmac-20200930.xml Edgar Link completed
dmac-20200930.xsd Edgar Link pending
dmac-20200930_cal.xml Edgar Link unprocessable
dmac-20200930_def.xml Edgar Link unprocessable
dmac-20200930_lab.xml Edgar Link unprocessable
dmac-20200930_pre.xml Edgar Link unprocessable
dmtp20200930_10q.htm Edgar Link pending
ex_210690.htm Edgar Link pending
ex_210691.htm Edgar Link pending
ex_210692.htm Edgar Link pending
ex_210693.htm Edgar Link pending
ex_210694.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
logo.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending